VIR vs KRSA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
VIR · Vir Biotechnology$8.39 ▼ 5.41%
KRSA · Korsana Biosciences$37.56 ▲ 5.95%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- VIR +37.1%
- KRSA +260.1%
Head to head
| Metric | VIR | KRSA |
|---|---|---|
| Price | $8.39 | $37.56 |
| Change today | ▼ 5.41% | ▲ 5.95% |
| Market cap | $1.56B | $1.71B |
| Return, 3 months | -15.3% | +36.5% |
| Return, year to date | +39.1% | +322.5% |
| Return, 1 year | +47.7% | +262.5% |
| P/E (TTM) | – | – |
| P/B | 1.7 | 4.4 |
| P/E percentile vs own 5y | 11th | 51st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -207.7% | – |
| Net profit growth (YoY) | +41.0% | -113.7% |
| Gross margin | 100.0% | – |
| Operating margin | -69.9% | – |
| Net margin | -61.1% | – |
| Return on equity | -21.8% | -23.2% |
| Analyst target vs. price | +167.3% | +36.3% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 33 | 70 |
| 30-day volatility | 92.6% | 60.0% |
| Max drawdown, 1 year | -38.5% | -54.7% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- KRSA is the largest of the group by market value.
- KRSA has returned the most over the past year.
- KRSA has been the calmest stock over the last 30 days.